Riemann, Donatus

[["dc.bibliographiccitation.firstpage","453"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The Journal of Clinical Psychiatry"],["dc.bibliographiccitation.lastpage","463"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Voderholzer, U."],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Berger, M."],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T09:00:49Z"],["dc.date.available","2018-11-07T09:00:49Z"],["dc.date.issued","2001"],["dc.description.abstract","Background: Over recent years, the use of antidepressants for the symptomatic treatment of insomnia has grown substantially, but controlled studies are still lacking. Our study is the first investigation to prove objective efficacy and tolerability of low doses of a sedating antidepressant in a randomized, double-blind, and placebo-controlled manner in patients with primary insomnia. Method: Forty seven drug-free patients meeting DSM-IV criteria for primary insomnia (mean +/- SD duration of complaints = 11.2 +/- 9.7 years) received either 25-50 mg of the tricyclic antidepressant doxepin or placebo for 4 weeks followed by 2 weeks of placebo withdrawal. Sleep was measured by polysomnography at baseline and the first night of application, at 4 weeks of treatment and the first to third night of withdrawal, and after 2 weeks of withdrawal. Results: In the doxepin-treated patients who completed the study (N = 20, 47.6 +/- 11.3), medication significantly increased sleep efficiency after acute (night 1, p less than or equal to .001) and subchronic (night 28, p less than or equal to .05) intake compared with the patients who received placebo (N = 20, 47.4 +/- 16.8 years of age). Latency to sleep onset was not affected since the patients had normal baseline sleep latencies. Investigators found doxepin to cause significantly (P less than or equal to .05) better global improvement at the first day of treatment. Patients rated sleep quality (p less than or equal to .001) and working ability (p less than or equal to .005) to be significantly improved by doxepin during the whole treatment period. Overall rebound in sleep parameters was not observed, but patients with severe rebound insomnia were significantly more frequent in the doxepin group (night 29, p less than or equal to .01; night 30, p less than or equal to .01; night 31, p less than or equal to .05). No significant group differences in side effects were Found, but 2 doxepin-treated patients dropped out of the study due to specific side effects (increased liver enzymes, leukopenia, and thrombopenia). Conclusion: The results support the effectiveness of low doses of doxepin to improve sleep and working ability in chronic primary insomniacs, although subjective effects were light to moderate, and in some patients, rebound insomnia and specific side effects have to be considered."],["dc.identifier.isi","000169918900009"],["dc.identifier.pmid","11465523"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24262"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Physicians Postgraduate Press"],["dc.relation.issn","0160-6689"],["dc.title","Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","165"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.lastpage","174"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Voderholzer, U."],["dc.contributor.author","Cohrs, Stefan"],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Wiegand, M. H."],["dc.contributor.author","Laakmann, G."],["dc.contributor.author","Baghai, T."],["dc.contributor.author","Fischer, W."],["dc.contributor.author","Hoffmann, M."],["dc.contributor.author","Hohagen, F."],["dc.contributor.author","Mayer, G."],["dc.contributor.author","Berger, M."],["dc.date.accessioned","2018-11-07T10:08:19Z"],["dc.date.available","2018-11-07T10:08:19Z"],["dc.date.issued","2002"],["dc.description.abstract","In recent years, sedating antidepressants have been increasingly used to treat primary insomnia. Up to now, only one open pilot study with trimipramine and one double-blind placebo-controlled study with doxepin have leant scientific support for this approach in treating primary insomnia. In order to test the hypothesis that sedating antidepressants are useful in the treatment of primary insomnia, the effect of trimipramine on objectively and subjectively measured parameters of sleep was investigated in a double-blind placebo- and lormetazepam-controlled study in a sample of 55 patients with primary insomnia attending outpatient sleep-disorder clinics. Trimipramine was selected since it has shown positive effects on sleep continuity with a lack of REM sleep suppression in studies on depressed patients and in one pilot study on patients with primary insomnia. Trimipramine at an average dose of 100 mg over a period of 4 weeks significantly enhanced sleep efficiency, but not total sleep time (which had been the primary target variable) compared to placebo as measured by polysomnography. Changes in objective sleep parameters were paralleled by changes in subjective sleep parameters. Trimipramine did not suppress REM sleep. Lormetazepam decreased wake time and sleep stage 3 and increased REM sleep compared to placebo. After switching trimipramine to placebo, sleep parameters returned to baseline. There was no evidence of any rebound effect from trimipramine. Side effects from trimipramine were only marginal. This first double-blind placebo-controlled study with trimipramine suggests its efficacy in the treatment of primary insomnia. However, due to the large intra- and interindividual variance in the parameters of interest before and during treatment a larger sample size would have been necessary to strengthen the validity of our findings."],["dc.identifier.doi","10.1055/s-2002-34119"],["dc.identifier.isi","000178383500002"],["dc.identifier.pmid","12237787"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39450"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0176-3679"],["dc.title","Trimipramine in primary insomnia: Results of a polysomnographic double-blind controlled study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0165-1781(02)00249-4"],["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Psychiatry Research"],["dc.bibliographiccitation.lastpage","27"],["dc.bibliographiccitation.volume","113"],["dc.contributor.author","Riemann, D."],["dc.contributor.author","Klein, T."],["dc.contributor.author","Rodenbeck, Andrea"],["dc.contributor.author","Feige, B."],["dc.contributor.author","Horny, A."],["dc.contributor.author","Hummel, R."],["dc.contributor.author","Weske, G."],["dc.contributor.author","Al-Shajlawi, A."],["dc.contributor.author","Voderholzer, U."],["dc.date.accessioned","2018-11-07T09:42:15Z"],["dc.date.available","2018-11-07T09:42:15Z"],["dc.date.issued","2002"],["dc.description.abstract","The present study investigated evening and nocturnal serum cortisol and melatonin concentrations in patients with primary insomnia to test if this clinical condition is accompanied by an increase of cortisol secretion and a simultaneous decrease of nocturnal melatonin production. Ten drug-free patients (4 males, 6 females) with primary insomnia (mean age +/- S.D.: 39.2 +/- 9.1 years) and 10 age- and gender-matched healthy controls participated in the study. All subjects spent three consecutive nights in the sleep laboratory with polysomnography. Measurement of cortisol and melatonin (from 19:00 h to 09:00 h) was performed prior to and during the last laboratory night. Contrary to expectation. cortisol secretion did not differ between healthy controls and insomniac patients. On the other hand, nocturnal melatonin production was significantly diminished in insomniac patients. Polysomnographically determined sleep patterns. in contrast to subjective ratings of sleep, demonstrated only minor alterations of sleep in the insomniac group. The lack of increased cortisol secretion in the patients with primary insomnia indicates that results from studies on the biological consequences of experimental sleep loss in healthy subjects cannot be applied to primary insomnia in general, especially if there are only minor objective sleep alterations. In spite of the negligible objective sleep disturbances in the present sample, nocturnal melatonin production was reduced, which tentatively suggests a role for this hormone in primary insomniacs. The pathophysiological significance of this finding is, however, still a matter of debate. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0165-1781(02)00249-4"],["dc.identifier.isi","000179989900002"],["dc.identifier.pmid","12467942"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33914"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ireland Ltd"],["dc.relation.issn","0165-1781"],["dc.title","Nocturnal cortisol and melatonin secretion in primary insomnia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]